Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q2 2018 · 10-Q
Revenue$29.38K$29.38K−11.4% vs Q2 2017 Net Income-$1.35M-$1.35MN/M vs Q2 2017 EPS Diluted$0.00$0.00— vs Q2 2017 Gross Profit$12,811−42.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flowderived-$352,657N/M Margins · derivedGross margin43.6%−23.3 pt vs Q2 2017
Operating margin-1143.1%+109.0 pt vs Q2 2017
Net margin-4594.4%−1233.1 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 17, 2018 · 48 d after period end